### 8.0 APPROPRIATE USE OF BLOOD COMPONENTS IN NEONATES AND PEDIATRIC PATIENTS

<table>
<thead>
<tr>
<th>Policy</th>
<th>The Transfusion Medicine Service follows established guidelines for the appropriate use and administration of blood products in neonates and pediatric patients.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reason</td>
<td>Aid in the efficacious use of blood components and products. Improve patient safety through judicious use of blood components and products.</td>
</tr>
</tbody>
</table>

#### Responsibilities of the Medical Director, Transfusion Medicine
- Be familiar with the use of and indications for the use of blood components and products in neonates and pediatric patients
- Be available to consult with treating physicians and other staff on the appropriate use and administration of blood products for neonates and pediatric patients
- Promote education of treating physicians and other staff in the appropriate use of blood components and products in neonates and pediatric patients including appropriate dosing/monitoring for effectiveness and reporting of transfusion reactions
- Initiate discussions with clinical staff when laboratory results and/or clinical setting suggest blood component or product use may, or may not, be indicated
- If applicable to hospital population, ensure guidelines for neonates and children are available

#### Responsibilities of Transfusion Medicine Service staff
- Perform all steps of applicable Transfusion Medicine Service procedures as written
- Consult with the Medical Director, Transfusion Medicine (or delegate) as indicated in technical procedures, or as necessary based on technologist’s skills and experience, or additional clinical or laboratory information

### REFERENCES
# 8.1 Neonatal Red Blood Cell and Platelet Transfusion

| Policy | The Transfusion Medicine Service follows established policies, processes and procedures for transfusion of blood components and products to neonatal patients. |
| Reason | Indications for transfusion and specific requirements for neonates are different from transfusion requirements for those over 4 months of age. |
| Responsibilities of the Medical Director, Transfusion Medicine | - Be familiar with indications for neonatal transfusion and be available for consultation with treating physicians  
- Ensure guidelines are readily available in institutions with neonates |
| Responsibilities of Transfusion Medicine Service staff | - Follow associated technical procedures as written  
- Consult with the Medical Director, Transfusion medicine (or delegate) as indicated by procedures or circumstances  
- Ensure requests for blood products meet hospital guidelines for indications and dosage |

## 8.2 Neonatal Patient Management

| General considerations | - A neonate is considered to be an infant up to 4 months of age  
- There is conflicting evidence for restrictive transfusion practices and for an effect on the long-term neurodevelopmental outcome in preterm infants exposed to severe anemia  
- Desirable hemoglobin levels vary with clinical circumstances (see table 8.1)  
- Transfusion solely to replace blood removed for laboratory tests is not recommended  
- All neonates should receive CMV-safe components |
| Red Blood Cell Dosage and Type | 10-15mL/kg body weight packed red blood cells that are:  
- Compatible with mother and neonate  
  » ABO group specific where possible  
  » Irradiated if previous intrauterine transfusion up to 40 weeks gestational age, exchange transfusion, complex cardiac abnormality until congenital immunodeficiency has been ruled out, massive transfusion (not necessary for low volume transfusion). |
| Massive Transfusion in a neonate (including exchange transfusion) | In addition to meeting the criteria in section above, units should be negative for hemoglobin S. |
| Compatibility testing – initial pre-transfusion examination | - Cord blood should not be used for pre-transfusion examinations  
- Required examinations include determination of ABO/RhD and  
- Antibody screen on a sample from the neonate or mother  
  » If clinically significant antibody(ies) are identified, the neonate must receive antigen negative units, compatible by antiglobulin crossmatch, until the antibody is no longer detectable in the infant’s serum/plasma |
| Compatibility testing – subsequent pre-transfusion examinations | - If the initial antibody screen is negative, repeat examination for unexpected antibodies may be omitted during the current hospital admission, up to 4 months of age. (Alloimmunization in a neonate is unlikely)  
- If a non-group O neonate needs to receive non-group O red blood cells that are incompatible with the maternal ABO group, the neonate’s serum/plasma should be examined for anti-A or anti-B by antiglobulin testing, and compatible blood should be used |
### Table 8.1: Threshold and Target Hemoglobin Levels for Neonatal Red Blood Cell Transfusion

<table>
<thead>
<tr>
<th>Transfuse neonate</th>
<th>If the hemoglobin result is</th>
<th>And the neonate is</th>
</tr>
</thead>
<tbody>
<tr>
<td>With acute blood loss</td>
<td>Any hemoglobin level</td>
<td>Hypotensive and ill.</td>
</tr>
<tr>
<td>Weaned off mechanical ventilation</td>
<td>&lt;100g/L</td>
<td>Requiring supplemental oxygen</td>
</tr>
</tbody>
</table>
| With anemia | <80g/L | Showing signs of anemia with:  
• Significant unexplained apnea  
• Persistent unexplained heart rate >165-180 bpm or respiratory rate > 80 per minute lasting >24 hours  
• Unexplained poor weight gain, 10g/day over 4-7 days despite adequate caloric intake (100-120 kcal/kg/day)  
• Unexplained lethargy |

| On ECMO or cyanotic heart disease | 120g/L | |

### Table 8.2: Indications for Neonatal Platelet Transfusion

<table>
<thead>
<tr>
<th>Transfuse if Neonate is</th>
<th>And the platelet count is</th>
<th>And clinical condition is</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any age up to 4 months</td>
<td>&lt;20x10⁹/L</td>
<td>any</td>
</tr>
<tr>
<td></td>
<td>__________________________</td>
<td>__________________________</td>
</tr>
<tr>
<td></td>
<td>&lt;50x10⁹/L</td>
<td>bleeding or invasive non-neuraxial procedure</td>
</tr>
<tr>
<td></td>
<td>__________________________</td>
<td>__________________________</td>
</tr>
<tr>
<td></td>
<td>&lt;100x10⁹/L</td>
<td>invasive neuraxial procedure</td>
</tr>
<tr>
<td>Premature</td>
<td>&lt;30x10⁹/L</td>
<td>stable, or Neonatal Alloimmune Thrombocytopenia</td>
</tr>
</tbody>
</table>

### REFERENCES

### 8.3 PEDIATRIC BLOOD COMPONENT TRANSFUSION

<table>
<thead>
<tr>
<th>Policy</th>
<th>The Transfusion Medicine Service follows established guidelines for the appropriate use and administration of blood components and products to pediatric patients.</th>
</tr>
</thead>
</table>
| Reason | • Indications for transfusion and specific blood component and product requirements differ between children and adults  
• Aid in the efficacious use of blood components and products  
• Improve patient safety through the judicious use of blood components and products |
| Applies to | Patients greater than 4 months of age up to patients of adult size or weight (e.g. >50kg) |
| Responsibilities of the Medical Director Transfusion Medicine | • Be familiar with the use of and indications for the use of blood components and products in the pediatric population  
• Where appropriate, ensure guidelines are in place for pediatric patients  
• Be available to consult with treating physicians and other staff in the appropriate use and administration of blood components and products for pediatric patients  
• Promote education of clinical and other staff in the appropriate use of blood components and products in pediatric patient including appropriate dosing/monitoring for effectiveness and reporting of transfusion reactions  
• Initiate discussion with clinical staff when laboratory results and/or clinical setting suggest blood component or product use may, or may not, be indicated for a pediatric patient |
| Responsibilities of Transfusion Medicine Service staff | • Follow appropriate technical procedures as written  
• Consult with the Medical Director, Transfusion Medicine (or delegate) as indicated in technical procedures, or as necessary based on the technologist’s skills and experience, additional laboratory examination results or the clinical situation  
• Consult Medical Director, Transfusion Medicine (or delegate) for requests not meeting hospital guidelines for indication and dosage |

**REFERENCES**

### Table 8.3: Pediatric Red Blood Cell Transfusion Guidelines

<table>
<thead>
<tr>
<th>Transfuse pediatric</th>
<th>Hemoglobin</th>
<th>And the child is or has</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical patient</td>
<td>&lt;60-70g/L</td>
<td>Pre-operative and alternate therapy is not available</td>
</tr>
<tr>
<td></td>
<td>&lt;80g/L</td>
<td>Post-operative and showing symptoms or signs of anemia</td>
</tr>
<tr>
<td>Severe cardiopulmonary disease</td>
<td>120g/L</td>
<td>Ongoing transfusion requirements</td>
</tr>
<tr>
<td>Chemotherapy or irradiation</td>
<td>&lt;70g/L</td>
<td>Ongoing transfusion requirements</td>
</tr>
<tr>
<td>Chronic anemia</td>
<td>&lt;70g/L</td>
<td>Symptomatic anemia unresponsive to medical therapy and not bleeding</td>
</tr>
<tr>
<td>Complications of sickle cell disease</td>
<td>Target 100 – 110g/L</td>
<td>Treatment or presentation of cerebro-vascular accident, acute chest syndrome, aplastic crisis, splenic sequestration, or pre-operative preparation. Refer to section 9.5</td>
</tr>
<tr>
<td>Thalassemia syndrome</td>
<td>Maintain at 90 – 100g/L</td>
<td>Chronic transfusion regimen</td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>Maintain &gt;70g/L</td>
<td>Suspected acute blood loss of 15% or more of blood volume</td>
</tr>
</tbody>
</table>
8.4 TRANSFUSION OF FROZEN PLASMA TO PEDIATRIC PATIENTS

**Appropriate uses include:**

- In conjunction with vitamin K for emergency reversal of warfarin effect in a patient requiring an urgent operative procedure or with life-threatening bleeding if Prothrombin Complex Concentrates are not available.*
- Active bleeding or major surgery with PT/aPTT results >1.5 x mid-range of age-related reference range
  - In the absence of heparin, LMWH, lepirudin, hirudin, or other FXa inhibitor, or lupus inhibitor
- Massive transfusion and clinical status precludes waiting for PT/aPTT results
- Acute DIC with bleeding
- Cardiopulmonary bypass procedures with hemorrhage and PT/PTT > 1.5 x mid-range of age-related reference range
- Preparation of reconstituted whole blood for exchange transfusion in neonates
- Hepatic failure with INR >1.5 and major bleeding or invasive procedure (other than para or thoracocentesis)
- Single coagulation factor deficiencies when alternative specific factor concentrates are not available (e.g. factor V, patient at remote location)
  - Specific factor concentrates should be made available as soon as possible, if necessary by transferring the patient to a centre where appropriate concentrates are available
- Rare plasma protein deficiencies for which alternative therapy is not immediately available (e.g. C1 esterase deficiency)
- Thrombotic thrombocytopenic purpura
  - Slow continuous transfusion while awaiting access to exchange transfusion

**Inappropriate uses include:**

- Hypovolemia
- Treatment of immunodeficiency states

*Note added in proof: “Dosage schedule for Prothrombin Complex Concentrate based on patient weight over 35 kg is provided in the National Advisory Committee Recommendations."

For children under 35kg anecdotal evidence suggests that Prothrombin Complex Concentrate is dosed as follows:  
- <10 kg INR <3, 250 IU; INR ≥ 3, 500 IU
- 10-25 kg INR <3, 500 IU; INR ≥ 3, 750 IU
- 25-35 kg INR <3, 750 IU; INR ≥ 3, 1,000 IU

**REFERENCES**

115. NAC, 2011.
8.5 TRANSFUSION OF PLATELETS TO PEDIATRIC PATIENTS MORE THAN 4 MONTHS OF AGE

Dose:
- Body weight <10kg: 5-10ml/kg apheresis or buffy coat platelets should increase platelet count 50 – 100 X 10⁹/L
- Body weight ≥10kg: 1 unit/10kg of apheresis or buffy coat platelets should increase platelet count 50 – 100 X 10⁹/L

Table 8.4 Indications for Pediatric Platelet Transfusion (other than neonate)

<table>
<thead>
<tr>
<th>Transfuse when platelet count is</th>
<th>And the child has</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;10 X 10⁹/L</td>
<td>Failure of platelet production with:</td>
</tr>
<tr>
<td></td>
<td>• active bleeding</td>
</tr>
<tr>
<td></td>
<td>• invasive procedure</td>
</tr>
<tr>
<td>&lt;50 X 10⁹/L</td>
<td>• serious bleeding</td>
</tr>
<tr>
<td></td>
<td>• major surgery</td>
</tr>
<tr>
<td></td>
<td>• invasive procedure with risk of major bleeding</td>
</tr>
<tr>
<td>&lt;100 X 10⁹/L</td>
<td>• Peri-neurosurgery</td>
</tr>
<tr>
<td></td>
<td>• Head injury</td>
</tr>
<tr>
<td></td>
<td>• Post operative cardiac surgery with significant bleeding</td>
</tr>
<tr>
<td>Any count</td>
<td>Platelet dysfunction with major bleeding</td>
</tr>
</tbody>
</table>

REFERENCES
8.6 MANAGEMENT OF CONGENITAL ANEMIAS (see also section 9, Special Transfusion Situations)

| Policy | The Transfusion Medicine Service has established policies, processes and procedures to assist in the management of patients with congenital anemias that include the provision of phenotypically matched units when appropriate. |
| Reason | Transfusion thresholds and indications for transfusion in patients with sickle cell syndromes, congenital hemolytic anemias or thalassemia syndromes may be different from those with other causes of anemia. |
| Responsibilities of the Medical Director, Transfusion Medicine | • Be familiar with the management of transfusion in patients with congenital anemias  
• Work in consultation with clinical staff in individual cases  
• Work in consultation with clinical staff to determine patient blood group phenotypes and decide on the optimal phenotype of units chosen for ongoing transfusion support  
• Establish policies and procedures for the provision of special products including: irradiated components, Hg S negative red blood cells  
and phenotypically matched red blood cells |
| Responsibilities of Transfusion Medicine Service staff | • Where possible, ensure full red blood cell phenotype (Rh, Kell, Duffy, Kidd, MNS) is performed prior to the first transfusion in a patient who will require ongoing transfusion support (refer to section 9.8 for list of antigens)  
• If the Transfusion Medicine Service does not have the capacity to perform these investigations, send samples to a regional reference laboratory or CBS requesting a full phenotype determination  
• Record results of phenotype determinations in the patient record  
• Provide phenotype compatible blood as determined by the Medical Director, Transfusion Medicine and appropriate clinical staff for subsequent transfusions  
• Check with CBS for availability of phenotype information |
| Patient Management | • Patients with inherited red blood cell membrane disorders should be transfused for the symptomatic relief of anemia  
• Non-alloimmunized patients with sickle cell syndromes should receive blood that is of the same Rh (D, C, c, E, e) and Kell phenotype  
• Sickle cell syndrome patients with detectable alloantibody should receive antigen negative blood and extended phenotype matched units when possible  
• Red cell units for children with sickle cell syndromes undergoing exchange transfusion should be negative for HbS if possible, because the post-transfusion hemoglobin S level is often measured to monitor the effectiveness of the exchange |

8.7 MANAGEMENT OF TRANSFUSION IN PEDIATRIC PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA

Refer to section 9.6

REFERENCES